UPDATE: Ranbaxy's generic of Novartis blockbuster Diovan approved for launch Approval good, a hit to Novartis but good news for Ranbaxy buyer Sun Pharmaceutical June 26, 2014 | By Eric Palmer The long-delayed and highly anticipated launch of generic Diovan is on the way, which is a bummer for Novartis ($NVS) and a huge boost for Indian drugmaker Ranbaxy Laboratories. It is also validation for the decision by Sun Pharmaceutical's owner, billionaire Dilip Shanghvi, who struck a $3.2 billion deal to buy Ranbaxy despite its years of FDA entanglements over quality issues. Reuters reported that the FDA has approved the drug, and sources tell Indian media that Ranbaxy will be launching its generic of the blockbuster blood pressure drug "immediately."
This is bad, the PC unit just lost a ton of cash. But don't worry we have plan to promote another drug just looking for the right opportunity. We still have Exelon Patch to sell hang in there. Maybe they will find a home office job for the entire sale force like they do with the managers. How some of these managers get moved inside I don't understand.
Divan helped me provide a nice living for my family until I left Novartis in 2012. It was a good run. Farewell Diovan. Enjoyed selling a product that was viewed as best in class. Great drug that has helped many people and will help even more as a low cost generic.
i still remember the dancing ARBs and terry bradshaw mispronuncing deeovan at the launch meeting. did all this 60 days after the merger of ciba and sandoz. fun time was had by all